• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    6/10/24 8:06:22 AM ET
    $ABIO
    $BCDA
    $BCLI
    $CERO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABIO alert in real time by email

    Gainers

    • Calidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million.
    • Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million.
    • CERo Therapeutics Hldgs (NASDAQ:CERO) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million.
    • Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 14.07% to $1.54. The company's market cap stands at $48.1 million.

    Losers

    • Sunshine Biopharma (NASDAQ:SBFM) stock fell 36.3% to $0.36 during Monday's pre-market session. The market value of their outstanding shares is at $6.7 million.
    • Skye Bioscience (NASDAQ:SKYE) shares fell 29.62% to $7.7. The market value of their outstanding shares is at $216.1 million.
    • CNS Pharma (NASDAQ:CNSP) stock decreased by 20.8% to $4.0. The company's market cap stands at $1.3 million.
    • ARCA biopharma (NASDAQ:ABIO) shares decreased by 14.03% to $2.82. The market value of their outstanding shares is at $40.9 million.
    • BioCardia (NASDAQ:BCDA) stock declined by 13.45% to $3.22. The market value of their outstanding shares is at $5.8 million.
    • Venus Concept (NASDAQ:VERO) stock fell 13.24% to $0.81. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $BCDA
    $BCLI
    $CERO

    CompanyDatePrice TargetRatingAnalyst
    Skye Bioscience Inc.
    $SKYE
    10/6/2025$2.00Buy → Hold
    Craig Hallum
    Skye Bioscience Inc.
    $SKYE
    10/6/2025$2.00Overweight → Neutral
    Cantor Fitzgerald
    Skye Bioscience Inc.
    $SKYE
    8/15/2025$10.00Outperform
    Evercore ISI
    CERo Therapeutics Holdings Inc.
    $CERO
    6/23/2025$30.00Hold → Buy
    D. Boral Capital
    Skye Bioscience Inc.
    $SKYE
    2/28/2025Outperform
    William Blair
    Skye Bioscience Inc.
    $SKYE
    9/30/2024$20.00Sector Outperform
    Scotiabank
    Skye Bioscience Inc.
    $SKYE
    9/10/2024$15.00Mkt Outperform
    JMP Securities
    Skye Bioscience Inc.
    $SKYE
    7/9/2024$18.00Buy
    Craig Hallum
    More analyst ratings

    $ABIO
    $BCDA
    $BCLI
    $CERO
    SEC Filings

    View All

    SEC Form S-8 filed by CNS Pharmaceuticals Inc.

    S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    2/27/26 5:22:40 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    2/27/26 4:24:56 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Skye Bioscience downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Skye Bioscience from Buy to Hold and set a new price target of $2.00

    10/6/25 12:17:16 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Skye Bioscience from Overweight to Neutral and set a new price target of $2.00

    10/6/25 10:31:53 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on Skye Bioscience with a new price target

    Evercore ISI initiated coverage of Skye Bioscience with a rating of Outperform and set a new price target of $10.00

    8/15/25 8:20:07 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement for an additional $1 million strategic private placement. This brings the total capital raised in February 2026 to $2 million. The financing is expected to reinforce a stable valuation for the company and provides the near-term resources required to advance its immediate regulatory and clinical objectives.Key Terms of the Second Placement:Market-Aligned Pricing: The common stock was priced at $0.60 per share, closely aligned with recent market performance (clo

    2/26/26 6:22:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

    2/23/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

    SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company's website. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloa

    2/20/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Schwab Andrew J.

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    2/9/26 9:06:29 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Grayson Paul A.

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    2/9/26 8:54:56 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Arsenault Kaitlyn

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    2/9/26 8:54:45 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Financials

    Live finance-specific insights

    View All

    CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

    Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity (DLT) observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion w

    1/7/26 9:09:00 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Leadership Updates

    Live Leadership Updates

    View All

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

    22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantageStrong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye")

    2/2/26 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $BCDA
    $BCLI
    $CERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CERo Therapeutics Holdings Inc.

    SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:06:55 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:01:41 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care